Tasly to invest up to RMB 3 bn in wealth management products

Tasly Pharmaceutical Group is set to invest up to RMB 3 billion of its idle funds in bank wealth management products. This decision, approved by the board on September 17, 2025, pending shareholder approval, aims to increase capital efficiency and generate better returns from its existing cash reserves. The investment will focus on low-to-medium risk income-generating products and bank structured deposits, specifically those with a risk rating of R2 or below. These products will not directly invest in high-risk securities like stocks, bonds, funds, or foreign exchange derivatives.

The authorization for these investments will be valid for one year from the date of shareholder approval, until October 9, 2026, with individual investment terms not exceeding six months. The company's management will have the flexibility to select specific products and banks based on market conditions within the approved framework. This strategic move is expected to bolster shareholder interests by optimizing the use of capital without impacting core business operations.

Tasly has implemented robust control measures, including a comprehensive "Cash Wealth Management System," to ensure the security of funds and adherence to regulatory requirements. While the chosen products are considered low-to-medium risk, the company acknowledges potential market, interest rate, liquidity, and credit risks, which could lead to fluctuations in returns.